Other studies will be useful to determine whether adrenomedullin infusion might improve renal dysfunction, as it has been shown to be beneficial after myocardial infraction. Further studies are needed to compare mAM and other humoral factors as predictive factors of mortality and morbidity in transplant patients. Further studies are necessary to clarify the pathophysiologic role of mAM in transplant patients complicated with various cardiovascular diseases (peripheral artery disease, stroke, heart failure, etc.) especially the diabetics who are most liable for these complications.